DNMT1 and diffuse large B-cell lymphoma: A subsequent phase I clinical pilot study evaluating the priming by DNMT inhibitor azacytidine (AZA) followed by standard R-CHOP in high-risk patients with DLBCL showed a very high rate of complete remission (92 %) and confirmed SMAD1 demethylation and chemosensitization [417].